Praxis Precision Medicines, Inc. (PRAX) Dividend History

Company News

• Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Praxis Precision Medicines, a clinical-stage biopharmaceutical company, announced that it granted a restricted stock unit award to a new non-executive employee under its 2024 Inducement Plan.

  GlobeNewswire Inc.
• Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Praxis Precision Medicines, a clinical-stage biopharmaceutical company, announced that it has granted restricted stock unit awards to five new non-executive employees under its 2024 Inducement Plan. The awards will vest over four years, subject to the employees' continued employment.

  GlobeNewswire Inc.
• Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

  The sodium channel blocker market is expanding due to the increasing prevalence of neuropathic pain and the rising incidence of cardiac arrhythmias. Over 20 pharmaceutical companies are actively developing 25+ pipeline sodium channel blockers, with promising drugs like Cenobamate, VX-548, and Vormatrigine in different clinical trial phases.

  GlobeNewswire Inc.

  Featured Companies: DWTX NBIX VRTX
• Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

  Praxis Precision Medicines, a clinical-stage biopharmaceutical company, will present data from its four late-stage programs in epilepsy and movement disorders at the American Academy of Neurology 2025 Annual Meeting. The company's innovative pipeline includes therapies for central nervous system disorders, with a focus on neuronal excitation-inhibition imbalance.

  GlobeNewswire Inc.

  Featured Companies: IONS
• Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Praxis Precision Medicines, a clinical-stage biopharmaceutical company, announced that it has granted non-qualified stock option awards and restricted stock unit awards to six new non-executive employees under its 2024 Inducement Plan.

  GlobeNewswire Inc.